BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan G, Liu Q, Tong D, Liu G, Yi Y, Zhang J, Zhang Y, Wang LA, Wang L, Chen R, Guan Y, Yi X, Lan W, Jiang J. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease. Cancer Biol Ther 2018;19:766-72. [PMID: 29947576 DOI: 10.1080/15384047.2018.1470732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Gläsker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther 2020;13:5669-90. [PMID: 32606780 DOI: 10.2147/OTT.S190753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
2 Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A; Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer 2021. [PMID: 34735022 DOI: 10.1002/cncr.33978] [Reference Citation Analysis]
3 Inayat F, Aleem S, Saif MW. Sunitinib as Successful Maintenance Therapy for Recurrent Pancreatic Serous Cystadenocarcinoma. Am J Ther 2020;28:e757-9. [PMID: 32541193 DOI: 10.1097/MJT.0000000000001205] [Reference Citation Analysis]
4 Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, Zhang D, Liu Q, Jiang J. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front Endocrinol (Lausanne) 2020;11:586857. [PMID: 33329393 DOI: 10.3389/fendo.2020.586857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
6 Lim-Fat MJ, Dietrich J. Myelopathies from Neoplasms. Semin Neurol 2021;41:291-302. [PMID: 34030192 DOI: 10.1055/s-0041-1725948] [Reference Citation Analysis]
7 Ma K, Hong B, Zhou J, Gong Y, Wang J, Liu S, Peng X, Zhou B, Zhang J, Xie H, Zhang K, Li L, Cai D, Wang Z, Cai L, Gong K. The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. Front Oncol 2019;9:1122. [PMID: 31737565 DOI: 10.3389/fonc.2019.01122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]